Yan Liu, Yinan Wang, Ahequeli Gemingnuer, Hailing Wang, Xin Meng
{"title":"肿瘤反应性纳米药物用于癌症治疗:设计原则和治疗进展。","authors":"Yan Liu, Yinan Wang, Ahequeli Gemingnuer, Hailing Wang, Xin Meng","doi":"10.1088/1748-605X/adf387","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor microenvironment (TME)-responsive nanomedicines have emerged as a promising precision therapeutic strategy in cancer treatment. By incorporating stimuli-responsive properties, these nanomedicines can achieve targeted delivery and controlled release at tumor sites, thereby enhancing therapeutic efficacy while minimizing side effects. This review provides a comprehensive overview of the latest advancements in TME-responsive nanomedicines for cancer immunotherapy, covering various stimulus-responsive mechanisms (such as pH, reactive oxygen species, hypoxia, enzymes, and ATP) and their applications in improving immune efficacy and reducing immune-related adverse effects. In addition to discusses the key challenges associated with the clinical translation of these nanomedicines and proposes future research directions. This work aims to offer a theoretical foundation and design reference for the further development and application of tumor-responsive nanomedicines.</p>","PeriodicalId":72389,"journal":{"name":"Biomedical materials (Bristol, England)","volume":"20 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor-responsive nanomedicines for cancer therapy: design principles and therapeutic advances.\",\"authors\":\"Yan Liu, Yinan Wang, Ahequeli Gemingnuer, Hailing Wang, Xin Meng\",\"doi\":\"10.1088/1748-605X/adf387\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tumor microenvironment (TME)-responsive nanomedicines have emerged as a promising precision therapeutic strategy in cancer treatment. By incorporating stimuli-responsive properties, these nanomedicines can achieve targeted delivery and controlled release at tumor sites, thereby enhancing therapeutic efficacy while minimizing side effects. This review provides a comprehensive overview of the latest advancements in TME-responsive nanomedicines for cancer immunotherapy, covering various stimulus-responsive mechanisms (such as pH, reactive oxygen species, hypoxia, enzymes, and ATP) and their applications in improving immune efficacy and reducing immune-related adverse effects. In addition to discusses the key challenges associated with the clinical translation of these nanomedicines and proposes future research directions. This work aims to offer a theoretical foundation and design reference for the further development and application of tumor-responsive nanomedicines.</p>\",\"PeriodicalId\":72389,\"journal\":{\"name\":\"Biomedical materials (Bristol, England)\",\"volume\":\"20 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical materials (Bristol, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1088/1748-605X/adf387\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical materials (Bristol, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1088/1748-605X/adf387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tumor-responsive nanomedicines for cancer therapy: design principles and therapeutic advances.
Tumor microenvironment (TME)-responsive nanomedicines have emerged as a promising precision therapeutic strategy in cancer treatment. By incorporating stimuli-responsive properties, these nanomedicines can achieve targeted delivery and controlled release at tumor sites, thereby enhancing therapeutic efficacy while minimizing side effects. This review provides a comprehensive overview of the latest advancements in TME-responsive nanomedicines for cancer immunotherapy, covering various stimulus-responsive mechanisms (such as pH, reactive oxygen species, hypoxia, enzymes, and ATP) and their applications in improving immune efficacy and reducing immune-related adverse effects. In addition to discusses the key challenges associated with the clinical translation of these nanomedicines and proposes future research directions. This work aims to offer a theoretical foundation and design reference for the further development and application of tumor-responsive nanomedicines.